




CYTOKINE RELEASE SYNDROME (CRS)

After CAR T-Cell Therapy



Screening with the Hyperinflammation Biochip

Biochip Array Technology enables rapid and precise multianalyte detection from a single patient sample, offering a highly sensitive screen for inflammation levels.



Biochip enables clinicians to accurately **identify CRS, triage and intervene immediately.**



Biochip improves patient outcomes through **rapid targeted treatment plans and trials.**



Biochip provides **real-time monitoring of CRS and treatment response after CAR T-Cell therapy**, enabling faster, tailored interventions.



Biochip could **reduce hospital stays** from 12 to 2 days.



EARLY DIAGNOSIS CAN MAKE A DIFFERENCE

The Hyperinflammation Biochip can aid intensive and critical care units to monitor the cytokine levels of patients who receive CAR T-cell therapy in real time. As clinicians apply various anti-inflammatory approaches, the patient's response can be monitored to ensure that the interventions are effective.

PROBLEM

Current lab-based tests have **long turnaround times** and require **batching**, **delaying diagnosis and treatment initiation**. Quick, case-by-case results are needed.

SOLUTION

Patient Pathway with Evidence MultiSTAT

- 1 Patient receives CAR T-cell therapy
- 2 Immediate testing with Evidence MultiSTAT on days 0, 1 and 2
- 3 Rapid identification of CRS within 60 minutes
- 4 Faster initiation of tailored treatment plans and monitoring



OUTCOME

Biochip enables clinicians to rapidly reduce cytokine levels, leading to better patient outcomes and quicker discharges.

Product Information



Sample Type
Plasma



Samples Per Cartridge
2



Sample Volume
400µl



Result Type
Quantitative



Time to Result
60 Minutes

Hyperinflammation Biochip Biomarkers

Interleukin-1 beta (IL-1 β)	Interleukin-2 (IL-2)
Interferon-gamma (IFN- γ)	Interleukin-15 (IL-15)
Interleukin-6 (IL-6)	Ferritin
D-Dimer	Tumour Necrosis Factor-alpha (TNF- α)
Monocyte Chemoattractant Protein-1 (MCP-1)	

Hyperinflammation Biochip – For use on the Evidence MultiSTAT analyser

marketing@randox.com | randox.com